Comparative Pharmacology
Head-to-head clinical analysis: EVOXAC versus SALAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOXAC versus SALAGEN.
EVOXAC vs SALAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
Pilocarpine is a cholinergic parasympathomimetic agent that acts as a muscarinic receptor agonist, stimulating exocrine gland secretion (salivary, sweat, lacrimal, gastric, pancreatic) and smooth muscle contraction.
30 mg orally three times daily.
5 mg orally three times daily.
None Documented
None Documented
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may be prolonged to 6-8 hours in elderly or those with hepatic impairment.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Renal excretion of unchanged drug and metabolites: 80-90% in urine, with approximately 20% unchanged; biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist